Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-UMIN000015733
JPRN-UMIN000015733CompletedPhase 1

Safety of cell immunotherapy for refractory malignant tumor using natural killer cell-like effector cells (CA-MED-NK001) selectively amplified from autologous mononuclear cells in peripheral blood - Safety of cell immunotherapy for refractory malignant tumor using CA-MED-NK001 cells

Center for Advanced Medical Innovation, Kyushu University0 sites10 target enrollmentStarted: November 21, 2014Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Completed
Sponsor
Enrollment
10
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This trial has been terminated due to the difficulties of the recruitment of condition-matched subjects after the entry of four patients.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20years-old to ot applicable (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •Patients to be excluded would satisfy any of the following conditions: (1) pulmonary fibrosis and/or interstitial pneumonia (2) patients who have a history of severe drug allergy (3) serum positive for HBs antigen, HCV, HTLV-1 and/or HIV antibody (4) active autoimmune disease (5) patients who are taking steroids and/or immunosuprresive agents (6) double or more cancers (7) uncontrolable infectious disease (8) Patients to be or wishing for pregnancy, or breast-feeding (9) T cell- or NK cell-originated leukemia and/or lymphoma (10) heavy cardiological disease (11) Patientss who are regarded as inadequate for study enrollment by the investigator

Investigators

Sponsor
Center for Advanced Medical Innovation, Kyushu University

Similar Trials

Completed
Phase 1
Combination therapy with immune-cell therapy and immune check point inhibitor.malignant tumor
JPRN-jRCTc031210185Takimoto Rishu3
Completed
Phase 2
Combination therapy with immune-cell therapy and immune check point inhibitormalignant tumor
JPRN-jRCTc031190100Takimoto Rishu40
Completed
Phase 2
Combination therapy with immune-cell therapy and immune check point inhibitormalignant tumor
JPRN-jRCTc031190098Takimoto Rishu40
Completed
Phase 2
Combination therapy with immune-cell therapy and immune check point inhibitormalignant tumor
JPRN-jRCTc031190099Takimoto Rishu40
Completed
Phase 2
A phase II study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinomagastric cancer
JPRN-UMIN000003201Study group of multi-modality therapy for gastric cancer5